Efficacy and safety of the first-in-class imidazoline-2 receptor ligand CR4056 in pain from knee osteoarthritis and disease phenotypes: a randomized, double-blind, placebo-controlled phase 2 trial.
Osteoarthritis and Cartilage（2020）
摘要
EudraCT 2015-001136-37.
更多查看译文
关键词
CR4056,Knee osteoarthritis,Imidazoline-2 receptor,Randomized controlled trial,Phenotypes
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要